Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 251 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment J Clear all
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Completed No phase listed Observational

Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP

NCT00550914
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis
Interventions
Not listed
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
1 Year to 12 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Diego, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Sep 2, 2026, 10:54 AM EDT
Not yet recruiting Not applicable Interventional

SwallowFIT Study in Parkinson's Disease

NCT07356414
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
SwallowFit
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
35 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Completed No phase listed Observational

Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)

NCT00001612
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 10:54 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III

NCT03433222
View directory record Official record
Conditions
Skin Diseases, Keloid, Scar, Fibrosis, Hypertrophic Skin
Interventions
HF-LED-RL Phototherapy, Mock Therapy
Device
Lead sponsor
VA Northern California Health Care System
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Laser Acupuncture Before and After Embryo Transfer Improves IVF Outcomes

NCT02815371
View directory record Official record
Conditions
Embryo Implantation
Interventions
Needle Acupuncture, Laser Acupuncture, Sham Laser Acupuncture
Procedure
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Norwalk, Connecticut • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction

NCT01212172
View directory record Official record
Conditions
Hypertrichosis
Interventions
Soprano/SHR, LightSheer
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Healthy Participants

NCT03929744
View directory record Official record
Conditions
Healthy
Interventions
LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

NCT01966809
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders

NCT04340622
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Dependence, Opioid Abuse
Interventions
supra-luminous LED, Sham
Device
Lead sponsor
MindLight, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Belmont, Massachusetts • Newton Highlands, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 2, 2026, 10:54 AM EDT
Not listed No phase listed Observational

Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations

NCT04944095
View directory record Official record
Conditions
Covid-19, Subjects Vaccinated Against Covid-19
Interventions
Change in SARS-CoV-2 Antibody Levels
Other
Lead sponsor
Dr. Sidney J. Stohs
Other
Eligibility
55 Years and older
Enrollment
10,000 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Southlake, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Sep 2, 2026, 10:54 AM EDT
Suspended Not applicable Interventional

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

NCT06934928
View directory record Official record
Conditions
Neurofibromatosis 1 (NF1), Neurofibromatosis Type I
Interventions
GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

NCT02602860
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[11C]UCB-J, Brivaracetam, Levetiracetam
Radiation · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 2, 2026, 10:54 AM EDT
Not listed Phase 2 Interventional

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

NCT05182866
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
ASP-1929 Photoimmunotherapy
Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Sep 2, 2026, 10:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation

NCT02468453
View directory record Official record
Conditions
Vascular Lesions, Photoaging
Interventions
velos
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
4
States / cities
San Diego, California • Wayland, Massachusetts • Edina, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Gepotidacin

NCT04493931
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 1 Interventional Results available

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

NCT01296555
View directory record Official record
Conditions
Solid Cancers, Non-Hodgkin's Lymphoma
Interventions
Fulvestrant, GDC-0032, Letrozole, Midazolam
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

NCT03386721
View directory record Official record
Conditions
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Interventions
simlukafusp alfa, Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
San Francisco, California • Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

NCT01707069
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Biological
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Not applicable Interventional Results available

Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure

NCT00939640
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (SRD)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bone Regenerative Techniques in Endodontic Microsurgery

NCT04514991
View directory record Official record
Conditions
Apical Periodontitis
Interventions
Foundation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma

NCT00862901
View directory record Official record
Conditions
Breast Cancer, Skin Cancer
Interventions
CLIPT patch
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression

NCT00961454
View directory record Official record
Conditions
Major Depression, Anxiety Disorder, Post-Traumatic Stress Disorder, Substance Abuse Disorder
Interventions
Photobiomodulation with a super-luminous light emitting diode
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2009 · Synced Sep 2, 2026, 10:54 AM EDT